Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.
Daisuke KawakitaToshitaka NagaoHideaki TakahashiSatoshi KanoYoshitaka HonmaHideaki HiraiNatsuki SaigusaKohei AkazawaKaori TaniHiroya OjiriKiyoaki TsukaharaHiroyuki OzawaKenji OkamiTakahito KondoTakafumi TogashiChihiro FushimiTomotaka ShimuraAkira ShimizuIsaku OkamotoTakuro OkadaYorihisa ImanishiYoshihiro WatanabeKuninori OtsukaAkihiro SakaiKoji EbisumotoYuichiro SatoKeisuke YamazakiYushi UekiToyoyuki HanazawaYuki SaitoMizuo AndoTakashi MatsukiMasato NakaguroYukiko SatoMakoto UranoYoshitaka UtsumiShinji KohsakaTakashi SaotomeYuichiro TadaPublished in: Therapeutic advances in medical oncology (2022)
Patients treated with HER2-targeted therapy and ADT showed longer survival in LA/RM SDC. HER2-targeted therapy can be recommended prior to ADT for HER2-positive/AR-positive SDC. It is warranted to establish a biomarker that could predict the efficacy of clinical benefit or better response in ADT.